bioMerieux partners with Sysmex

bioMerieux has announced details of a new agreement which provides Sysmex with a 34 per cent equity stake in bioMerieux Japan.

The resulting company, Sysmex bioMerieux, will promote the in vitro diagnostics company’s entire range throughout Japan.

Stephane Bancel, chief executive officer of bioMerieux said: "We are extremely pleased to engage in this joint venture with Sysmex for the Japanese market.

"To date, bioMerieux Japan is number 19 in the Japanese IVD market, while bioMerieux is number seven worldwide.

"We have been lacking scale in several critical functions like commercial operations and customer service. By partnering with the number one diagnostics company in the Japanese market, we will bring bioMerieux’s innovative products to a broader Japanese customer base."

According to the company, market volume of microbiology testing in Japan is estimated at approximately 30 billion Japanese yen per year and regarded as a strategically important market, the second largest in size worldwide.